ASX Penny Stocks To Watch With Market Caps Under A$200M

As the Australian market faces a challenging week with futures down and global tariff tensions looming, investors are keenly observing potential opportunities. Despite its somewhat outdated name, the concept of penny stocks remains relevant for those interested in smaller or newer companies that might offer substantial value. By focusing on firms with solid financial foundations and growth potential, investors can uncover hidden gems within this sector.

Advertisement

Top 10 Penny Stocks In Australia

NameShare PriceMarket CapRewards & Risks
Alfabs Australia (ASX:AAL)A$0.40A$114.64M✅ 3 ⚠️ 3 View Analysis >
EZZ Life Science Holdings (ASX:EZZ)A$2.03A$95.76M✅ 4 ⚠️ 2 View Analysis >
GTN (ASX:GTN)A$0.57A$108.68M✅ 3 ⚠️ 2 View Analysis >
IVE Group (ASX:IGL)A$2.95A$454.84M✅ 4 ⚠️ 2 View Analysis >
West African Resources (ASX:WAF)A$2.35A$2.68B✅ 5 ⚠️ 1 View Analysis >
Southern Cross Electrical Engineering (ASX:SXE)A$1.775A$469.33M✅ 4 ⚠️ 1 View Analysis >
Regal Partners (ASX:RPL)A$2.92A$981.78M✅ 4 ⚠️ 2 View Analysis >
Sugar Terminals (NSX:SUG)A$0.99A$360M✅ 2 ⚠️ 2 View Analysis >
Austco Healthcare (ASX:AHC)A$0.37A$134.79M✅ 4 ⚠️ 1 View Analysis >
CTI Logistics (ASX:CLX)A$1.86A$149.81M✅ 4 ⚠️ 2 View Analysis >

Click here to see the full list of 460 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

CleanSpace Holdings (ASX:CSX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CleanSpace Holdings Limited designs, manufactures, and sells respiratory protection products and services for healthcare and industrial markets globally, with a market cap of A$59.48 million.

Operations: The company generates revenue of A$17.61 million from its respiratory products segment.

Market Cap: A$59.48M

CleanSpace Holdings, with a market cap of A$59.48 million, is navigating the challenges of being unprofitable while generating A$17.61 million in revenue from its respiratory products. Despite its negative return on equity and increasing losses over the past five years, it has managed to reduce its debt-to-equity ratio significantly from 51.9% to 14.8%. The company's short-term assets comfortably cover both short- and long-term liabilities, indicating financial stability in the near term. However, the management team lacks extensive experience with an average tenure of 1.9 years, which could impact strategic execution moving forward.

ASX:CSX Financial Position Analysis as at Aug 2025
ASX:CSX Financial Position Analysis as at Aug 2025

Sandon Capital Investments (ASX:SNC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Sandon Capital Investments Limited is a publicly owned investment manager with a market capitalization of A$129.27 million.

Operations: The company's revenue is derived entirely from Investing Activities, totaling A$23.02 million.

Market Cap: A$129.27M

Sandon Capital Investments, with a market cap of A$129.27 million, shows financial resilience as its short-term assets (A$167.4M) exceed both short- and long-term liabilities. The company's net profit margins have improved to 70.7%, although it faced negative earnings growth over the past year, contrasting with the industry average growth of 23.4%. Its debt is not well covered by operating cash flow but remains manageable due to more cash than total debt and strong interest coverage by EBIT (9.1x). Despite a low return on equity at 12.6%, its price-to-earnings ratio suggests it may be undervalued compared to the broader Australian market.

ASX:SNC Financial Position Analysis as at Aug 2025
ASX:SNC Financial Position Analysis as at Aug 2025

Shaver Shop Group (ASX:SSG)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shaver Shop Group Limited operates as a retailer of personal care and grooming products in Australia and New Zealand, with a market cap of A$193.90 million.

Operations: The company's revenue is primarily generated through retail store sales of specialist personal grooming products, amounting to A$218.14 million.

Market Cap: A$193.9M

Shaver Shop Group Limited, with a market cap of A$193.90 million, operates debt-free and demonstrates financial stability as its short-term assets (A$62.1M) exceed both short- and long-term liabilities. The company has experienced negative earnings growth over the past year (-6.1%), yet forecasts suggest a 7.96% annual growth in earnings moving forward. Despite a decline in net profit margins from 7.1% to 6.7%, Shaver Shop's seasoned management team and high-quality past earnings contribute to its resilience in the market, trading at 54.3% below estimated fair value without significant shareholder dilution recently observed.

ASX:SSG Revenue & Expenses Breakdown as at Aug 2025
ASX:SSG Revenue & Expenses Breakdown as at Aug 2025

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About ASX:SSG

Shaver Shop Group

Engages in retailing personal care and grooming products in Australia and New Zealand.

Flawless balance sheet, good value and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
48 users have followed this narrative
2 users have commented on this narrative
8 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
69 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
188 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0